• By Meagan Farmer
  • Posted December 8, 2023

A Genetic Counselor’s Experience with Proactive Reanalysis through Patient for Life: An Interview with Kelly Minks, MS, CGC

At the National Society for Genetic Counselors Annual Conference, I had the chance to sit down with Kelly Minks, MS, CGC. Ms. Minks is a genetic counselor in the Department of Neurology at the University of Rochester Medical Center, with a clinical practice focused on pediatric neurology. She routinely orders exome testing for children with developmental…


  • By Andrew Giles, MS, CGC
  • Posted December 5, 2023

Addressing equity in exome sequencing: Proactive reanalysis through the Ambry Patient for Life program helps to reduce racial, ethnic, and ancestral disparities

We know there are healthcare disparities among racial and ethnic groups; these disparities also impact genetic testing. Research and clinical studies have lacked diverse representation and have been predominantly composed of people with European ancestry. As rates of testing have rapidly increased, this gap has only widened. This means much of…


  • By Tawanna St. Lewis, MS, CGC
  • Posted November 20, 2023

Guest Blog: The Importance of Family Health History

My name is Tawanna St. Lewis, and I have been a genetic counselor for going on seven years now. My love for the profession continues to grow. I remain passionate about my role because I enjoy speaking with and helping patients, and I genuinely appreciate it when patients feel comfortable enough to share their health history and family history.…


  • By Kristina O'Quinn
  • Posted October 25, 2023

Off My Chest: How Negative Genetic Testing and a Supportive Community Helped Me Navigate Breast Cancer

In the fall of 2021, my eighteen-year-old child was making an appointment for an annual check-up, then handed me the phone and said, “Mom, don’t you need a check-up? Didn’t you miss your appointment last year because of COVID?” I had, in fact, missed my annual check-up and mammogram. A few days later, after the check-up and mammogram, I…


  • By Meagan Farmer
  • Posted October 18, 2023

Breast Cancer Awareness Month: CHEK2 with Petra Kleiblova and Zdenek Kleibl

Amby Genetics is proud to have worked with a large international team on clarifying the significance of CHEK2 variants. We connected with team leaders Dr. Petra Kleiblova and Dr. Zdenek Kleibl ahead of Breast Cancer Awareness Month. They provided us with the following commentary on the importance of the recent publication, “ENIGMA CHEK2gether…


  • By Jessica Grzybowski, MS, CGC
  • Posted October 17, 2023

Understanding Gene-Disease Validity in Breast Cancer: The Power of Evidence

When it comes to understanding the genetic basis of diseases, evidence plays a crucial role. Gene-disease validity measures the strength of evidence associating pathogenic variants or changes in a gene to a genetic disease or syndrome. In the context of breast cancer, which affects approximately 1 in every 8 women, grasping gene-disease validity…


  • By Meagan Farmer
  • Posted September 27, 2023

Ambry Spotlight: BRCAResponder Amy Byer Shainman

Amy Byer Shainman, also known as BRCAResponder, is a patient advocate, author, and producer who provides support and education related to having a pathogenic variant in BRCA1/2 or other cancer predisposition genes. We connected with her ahead of National Previvor Day and Hereditary Breast and Ovarian Cancer Week. Amy’s sister was diagnosed…


  • By Meghan Towne, MS, CGC, LCGC
  • Posted September 20, 2023

Genetics in Medicine publication demonstrates a 10% lower rate of VUS with WES/WGS compared to panels

Are uncertain results (variants of uncertain significance, or VUS) more likely in multi-gene panels (MGP) or whole exome- and genome-based (WES/WGS) tests? Ambry recently participated in a study led by the Medical Genomic Initiative (MGI) comparing the VUS rates for MGP and WES/WGS. The study, conducted across 19 clinical laboratories in North…


  • By Ashley Thompson
  • Posted September 14, 2023

Ovarian Cancer Awareness Month Spotlight: Norma Livingston Ovarian Cancer Foundation

Norma was a healthy, active 65-year-old woman who was rarely sick and had always been proactive about her health. She went to her internist complaining of weight gain, abdominal discomfort, and a chronic cough. When the diagnosis was finally made, Norma had stage 4 ovarian cancer. She endured nine hours of surgery, countless rounds of chemotherapy,…


  • By Meagan Farmer
  • Posted August 9, 2023

Her Healthcare: Leveraging the CARE Program to Scale High-Risk Patient Identification

We recently met with Texas OB/GYN, Dr. Noel Boyd. We learned about her passion for caring for the whole patient and helping to identify those at increased risk for cancer so that they can make proactive choices to address their risk. Dr. Boyd’s practice implemented The CARE ProgramTM, which stands for “Comprehensive Assessment of Risk and…